Related Experiment Videos
Treatment of hypertension in the elderly
1Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi G D'Annunzio, Chieti. g.abate@dmsi.unich.it
Insights
Antihypertensive drugs effectively reduce cardiovascular events in elderly patients. However, caution is advised when applying trial results to diverse patient populations with comorbidities.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Background:
- Elderly patients with hypertension benefit from antihypertensive drugs, reducing cardiovascular events.
- Existing trials often exclude patients with target organ damage, cognitive impairment, or significant comorbidities.
- This limits the direct applicability of trial findings to real-world clinical practice.
Purpose of the Study:
- To evaluate the efficacy of antihypertensive drugs in elderly patients.
- To highlight the need for cautious interpretation of trial results due to patient selection criteria.
- To discuss therapeutic considerations for hypertensive patients with comorbidities.
Main Methods:
- Review of existing clinical trial data on antihypertensive drug efficacy in the elderly.
- Analysis of patient characteristics in key hypertension trials.
- Discussion of treatment strategies based on associated comorbidities.
Main Results:
- Antihypertensive medications are effective in systolic-diastolic and isolated systolic hypertension in the elderly.
- Trials predominantly included healthy, independent elderly individuals with minimal comorbidity.
- Treatment approaches must be individualized based on the presence and nature of associated diseases.
Conclusions:
- Trial results for antihypertensive drugs in the elderly require cautious application in clinical practice.
- Management of hypertension in elderly patients with comorbidities necessitates tailored, aggressive, or interaction-aware strategies.
- Preventing sudden blood pressure drops is crucial to avoid target organ ischemia.
Abstract:
Several trials performed in elderly patients have demonstrated that antihypertensive drugs are effective in both systo-diastolic and isolated systolic hypertension, reducing the incidence of fatal and nonfatal cardiovascular events. However because of technical and design problems, the studies carried out to date have involved highly selected patients, almost always without any target organ damage, independent, cognitively normal and with low comorbidity. Therefore, trial results may be transferred to clinical practice only with some caution. Therapeutic behavior could be different in the presence of diseases associated with hypertension: a) in case of associated specific cardiovascular complications and/or diseases, such as diabetes or dyslipidemia, which could increase cardiovascular risk, treatment must be more aggressive; b) in case of associated diseases with fatal prognosis, treatment is aimed at preventing hypertensive emergencies; c) in case of associated diseases, which are not life-threatening but require chronic pharmacological intervention, drug interaction must be carefully considered. Finally, sudden and significant blood pressure drops due both to overdosage of antihypertensive drugs and/or to intercurrent illnesses must be prevented, because the reduction of blood flow may induce severe target organ ischemia.